# TIMES: Ticagrelor vs. Placebo/ Clopidogrel With Aspirin in Anterior STEMI Patients Treated With Primary PCI

Study · id `cardio:ct-nct03145194` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03145194](<https://clinicaltrials.gov/study/NCT03145194>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03145194

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 140 participants.

## Technical summary

Registry record NCT03145194. Randomized; triple masking; primary purpose treatment. Start 2017-01-30 (actual); primary completion 2018-11-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 140 participants (planned count; ClinicalTrials.gov record NCT03145194, source copy `cardio:ctgov-nct03145194-2017-05-30`, retrieved 2026-10-26)
- Started: 2017-01-30 (actual) (ClinicalTrials.gov record NCT03145194, source copy `cardio:ctgov-nct03145194-2017-05-30`, retrieved 2026-10-26)
- Primary completion: 2018-11-30 (anticipated) (ClinicalTrials.gov record NCT03145194, source copy `cardio:ctgov-nct03145194-2017-05-30`, retrieved 2026-10-26)
- Completion: 2019-11-30 (anticipated) (ClinicalTrials.gov record NCT03145194, source copy `cardio:ctgov-nct03145194-2017-05-30`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT03145194, source copy `cardio:ctgov-nct03145194-2017-05-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03145194-2017-05-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: TIMES: Ticagrelor vs. Placebo/ Clopidogrel With Aspirin in Anterior STEMI Patients Treated With Primary PCI
- Condition: ST Elevation Myocardial Infarction
- Intervention (Drug): Ticagrelor
- Intervention (Other): Placebo
- Lead sponsor: Papworth Hospital NHS Foundation Trust
- Lead sponsor class: OTHER\_GOV
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- Registry lists this organization as the lead sponsor: Papworth Hospital NHS Foundation Trust (`cardio:org-papworth-hospital-nhs-foundation-trust`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: a0bbea5717a0584bbe2fe3664600d90123713a4833ef1c630cac70885388e891
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
